• Ariane Stollenwerk, Melanie Sohns, Fabian Heisig, Christian Elling, and Detlef von Zabern.
• Grünenthal GmbH, Aachen, Germany. ariane.stollenwerk@grunenthal.com.
• Adv Ther. 2018 Jan 1; 35 (1): 12-30.

IntroductionTapentadol is a centrally acting analgesic that has been available for the management of acute and chronic pain in routine clinical practice since 2009.MethodsThis is the first integrated descriptive analysis of post-marketing safety data following the use of tapentadol in a broad range of pain conditions relating to the topics overall safety, dose administration above approved dosages, administration during pregnancy, serotonin syndrome, respiratory depression, and convulsion. The data analyzed pertain to spontaneous reports from healthcare and non-healthcare professionals and were put in the context of safety information known from interventional and non-interventional trials.ResultsThe first years of routine clinical practice experience with tapentadol have confirmed the tolerability profile that emerged from the clinical trials. Moreover, the reporting of expected side effects such as respiratory depression and convulsion was low and no major risks were identified. The evaluation of available post-marketing data did not confirm the theoretical risk of serotonin syndrome nor did it reveal unexpected side effects with administration of higher than recommended doses.ConclusionMore than 8 years after its first introduction, the favorable overall safety profile of tapentadol in the treatment of various pain conditions is maintained in the general population.FundingGrünenthal GmbH.

30 keywords...

hide…